These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 35217809)

  • 61. IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
    Xu J; Wang Y; Khoshdeli M; Peach M; Chuang JC; Lin J; Tsai WW; Mahadevan S; Minto W; Diehl L; Gupta R; Trauner M; Patel K; Noureddin M; Kowdley KV; Gulamhusein A; Bowlus CL; Huss RS; Myers RP; Chung C; Billin AN
    Hepatology; 2023 Jan; 77(1):20-32. PubMed ID: 35686937
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
    Cao S; Yang X; Zhang Z; Wu J; Chi B; Chen H; Yu J; Feng S; Xu Y; Li J; Zhang Y; Wang X; Wang Y
    Eur J Med Chem; 2022 Feb; 230():114089. PubMed ID: 34998040
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
    Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
    Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
    Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
    Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
    Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
    mSystems; 2016; 1(5):. PubMed ID: 27822554
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design and Structural Optimization of Dual FXR/PPARδ Activators.
    Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
    J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Farnesoid X receptor (FXR): Structures and ligands.
    Jiang L; Zhang H; Xiao D; Wei H; Chen Y
    Comput Struct Biotechnol J; 2021; 19():2148-2159. PubMed ID: 33995909
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice.
    Lin C; Yu B; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Front Pharmacol; 2022; 13():880508. PubMed ID: 35614939
    [No Abstract]   [Full Text] [Related]  

  • 74. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor.
    Zheng Z; Zhao Z; Li S; Lu X; Jiang M; Lin J; An Y; Xie Y; Xu M; Shen W; Guo GL; Huang Y; Li S; Zhang X; Xie W
    Mol Pharmacol; 2017 Oct; 92(4):425-436. PubMed ID: 28739572
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of farnesoid X receptor and its role in bile acid metabolism.
    Chiang JYL; Ferrell JM
    Mol Cell Endocrinol; 2022 May; 548():111618. PubMed ID: 35283218
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.
    Gonzalez FJ; Jiang C; Patterson AD
    Gastroenterology; 2016 Nov; 151(5):845-859. PubMed ID: 27639801
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
    J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.